Japanese specialty drug makers Maruishi Pharmaceutical and Yoshida Pharmaceutical announced Feb. 23 the withdrawal of a planned merger. The two companies signed a collaboration agreement in September. However, the two have many overlapping products and product integration is estimated to take longer than planned. Maruishi and Yoshida are among top three drug makers for sterilization products and pharmacopeia preparations in Japan. (Click here for more - Japanese language
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.
The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.
US green light will further expand sales of the prostate cancer blockbuster.
